Equities Analysts Set Expectations for BCRX FY2026 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Cantor Fitzgerald decreased their FY2026 EPS estimates for BioCryst Pharmaceuticals in a report issued on Wednesday, October 15th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the biotechnology company will post earnings per share of $0.01 for the year, down from their prior forecast of $0.45. Cantor Fitzgerald has a "Overweight" rating and a $26.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.12. The business had revenue of $163.35 million during the quarter, compared to analysts' expectations of $149.59 million. During the same period in the prior year, the business posted ($0.06) EPS. The business's revenue was up 49.5% on a year-over-year basis.

Several other analysts also recently issued reports on BCRX. Needham & Company LLC increased their price target on BioCryst Pharmaceuticals from $17.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday. Zacks Research upgraded BioCryst Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Monday, October 6th. Bank of America lifted their price target on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Tuesday, July 1st. Evercore ISI reaffirmed an "in-line" rating and set a $8.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 1st. Finally, JMP Securities raised their price objective on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a "market outperform" rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $19.18.

BioCryst Pharmaceuticals Trading Down 1.3%

Shares of NASDAQ BCRX opened at $6.72 on Friday. BioCryst Pharmaceuticals has a 12-month low of $6.00 and a 12-month high of $11.31. The company has a market cap of $1.41 billion, a P/E ratio of -37.33, a P/E/G ratio of 1.43 and a beta of 1.05. The stock has a fifty day moving average price of $7.87 and a 200 day moving average price of $8.64.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BCRX. Arrowstreet Capital Limited Partnership boosted its stake in BioCryst Pharmaceuticals by 2,103.7% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company's stock valued at $38,336,000 after purchasing an additional 4,084,403 shares during the period. Assenagon Asset Management S.A. boosted its stake in BioCryst Pharmaceuticals by 25,631.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company's stock valued at $32,441,000 after purchasing an additional 3,606,566 shares during the period. Millennium Management LLC boosted its stake in BioCryst Pharmaceuticals by 382.6% during the 1st quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock valued at $28,597,000 after purchasing an additional 3,022,769 shares during the period. Qube Research & Technologies Ltd boosted its stake in BioCryst Pharmaceuticals by 152.3% during the 2nd quarter. Qube Research & Technologies Ltd now owns 2,373,489 shares of the biotechnology company's stock valued at $21,266,000 after purchasing an additional 1,432,824 shares during the period. Finally, Nuveen LLC bought a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter worth about $10,677,000. 85.88% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the business's stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the transaction, the director directly owned 65,352 shares of the company's stock, valued at $556,145.52. The trade was a 51.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.10% of the stock is owned by insiders.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.